Splicing up the Diagnosis: Using Targeted RNA Studies to **Reclassify Exome Sequencing Variants** Meghan Towne, Jessica Grzybowski, Jessica Gage, Jesus Ramirez Castano, Heather Zimmermann

BACKGROUND

- RNA analysis is valuable for providing evidence for variant classification • Whole transcriptome (WTS) improves exome sequencing (ES) diagnostic yield
- However, WTS is not yet feasible for all exome patients
- Targeted RNA studies provide many of the same benefits as WTS
- Careful selection of variants for RNA studies maximize the efficiency and efficacy


AIM: Review ES cases between 2017-2021 with variant reclassification due to targeted RNA studies

RESULTS

- 9 cases were reclassified based on RNA evidence [Table 1]
- Prior to ES, all were undiagnosed after extensive genetic testing [Figure 2] • Clinical indications reflect typical clinical ES cohort [Figure 3]

TABLE 1: RECLASSIFED VARIANTS Classification with Nucleotide change Case Gene RNA evidence VUS FOXP1 c.1652+5G>C VUS ANKRD11 c.226G>A VUS TNNT1 c.32+5G>A VUS ADNP c.201G>C VUS c.104+3 104+6delAAGT FMR1 VUS TRIP12 c.4190+5G>A 6 VUS FOXP1 c.1531-9 1534dup13 VUS PTEN c.210-12C>G

SPG11 c.5866+5G>C 9 **FIGURE 3: INDICATION FOR** TESTING



- Multiple congenital anomalies
- Muscular dystrophy
- Neurodevelopmental
- Ataxia/ spasticity

VUS

- Global developmental delay, Autism spectrum disorder, auditory hallucinations, and dysmorphic features
- Karyotype, CMA, and Fragile X normal
- c.4190+5G>A

out	Classification with RNA evidence
	Р
	Р
	Р
	LP
	Р
	Р
	Р
	LP
	LP

gene-disease

of disease for splicing

CASE EXAMPLE

Neurodevelopmental panel: POLG VUS which was found to be paternally inherited on ES ES revealed a VUS in *TRIP12* RNA studies by the ATG lab resulted in a reclassification to pathogenic

• Collective 45.5% abnormal splicing observed [Figure 4]

